Table 1 Baseline characteristics of neoadjuvant vs. adjuvant immunotherapy
Variable | Neoadjuvant immunotherapy 408 (77.57%) | Adjuvant immunotherapy 118 (22.43%) | Total 526 | P | |
|---|---|---|---|---|---|
Age at diagnosis: median (range) | 62 (34 -88) | 62.5 (29-86) | 62.00 (29–88) | 0.541 | |
Sex | Male | 238 (58.33) | 62 (52.54) | 300 (57.03) | Â |
Female | 170 (41.67) | 56 (47.46) | 226 (42.97) | 0.263 | |
Race | White | 359 (90.43) | 113 (96.58) | 472 (91.83) | 0.049 |
Black | 21 (5.29) | 4 (3.42) | 25 (4.86) | Â | |
Other | 17 (4.28) | 0 (0.00) | 17 (3.31) | Â | |
Unknown | 11 | 1 | 12 | Â | |
Education | > = 13% HG | 112 (27.72) | 29 (24.58) | 141 (27.01) | 0.498 |
< 13% | 292 (72.28) | 89 (75.42) | 381 (72.99) |  | |
Unknown | 4 | 0 | 4 | Â | |
Income | > = $35,000 | 292 (72.28) | 89 (75.42) | 381 (72.99) |  |
< 35,000 | 112 (27.72) | 29 (24.58) | 141 (27.01) | 0.498 | |
Unknown | 4 | 0 | 4 | Â | |
Place of Living | Urban | 384 (98.71) | 115 (99.14) | 499 (98.81) | Â |
Rural | 5 (2.29) | 1 (0.86) | 6 (1.19) | 0.712 | |
Unknown | 19 | 2 | 21 | Â | |
Hospital Type | Academic | 318 (78.91) | 95 (82.61) | 413 (79.73) | Â |
Community | 85 (21.09) | 20 (17.29) | 109 (20.27) | 0.384 | |
Unknown | 5 | 3 | 8 | Â | |
Insurance Status | Insured | 398 (98.51) | 118 (100.00) | 516 (98.85) | Â |
Not insured | 6 (1.49) | 0 (0.00) | 6 (1.15) | 0.183 | |
Unknown | 4 | 0 | 4 | Â | |
Charlson/Deyo Score | 0 | 303 (74.26) | 88 (74.58) | 391 (74.33) | Â |
1 | 89 (21.81) | 25 (21.19) | 114 (21.67) | Â | |
> = 2 | 16 (3.92) | 5 (4.24) | 21 (3.99) | 0.980 | |
Year of Diagnosis | 2004–2010 | 238 (58.33) | 40 (33.90) | 278 (52.85) | 0.0001 |
2011–2016 | 170 (41.67) | 78 (66.10) | 248 (47.15) |  | |